BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics,
Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis
Pharmaceuticals, Inc., announced today that it will host a live
webcast on Tuesday, August 4 at
4:30 p.m. Eastern Time to discuss its
second quarter 2020 financial results and report on pipeline and
business progress.
Interested parties may listen to the call by dialing
1-888-317-6003, passcode 9496130, or access the webcast
at https://www.webcaster4.com/Webcast/Page/2327/35686. A
webcast replay will be available for a limited time at the same
address.
ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics, Inc., a
majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:
IONS), is a biopharmaceutical company focused on developing and
commercializing medicines to treat patients with serious and rare
diseases. Akcea is commercializing TEGSEDI® (inotersen)
and WAYLIVRA® (volanesorsen), as well as advancing a
mature pipeline of novel medicines, including
AKCEA-APO(a)-LRx, vupanorsen (AKCEA-ANGPTL3-LRx),
AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with
the potential to treat multiple diseases. All six medicines were
discovered by Ionis, a leader in antisense therapeutics, and are
based on Ionis' proprietary antisense technology. TEGSEDI is
approved in the U.S., E.U., Canada and Brazil,
and WAYLIVRA is approved in the E.U. Akcea is headquartered
in Boston, Massachusetts, and
is building the infrastructure to commercialize its medicines
globally. Additional information about Akcea is available
at www.akceatx.com and you can follow the Company on Twitter at
@akceatx.
FORWARD-LOOKING STATEMENT
This press release includes
forward-looking statements regarding the business of Akcea
Therapeutics, Inc. Any statement
describing Akcea's goals, expectations, financial or
other projections, intentions or beliefs, including the commercial
potential of Akcea's medicines in development is a
forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing medicines that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such
medicines. Akcea's forward-looking statements also
involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements.
Although Akcea's forward-looking statements reflect the
good faith judgment of its management, these statements are based
only on facts and factors currently known by Akcea. In
particular, we caution you that our forward-looking statements
are subject to the ongoing and developing circumstances related to
the COVID-19 pandemic, which may have a material adverse effect on
our business, operations and future financial results. As a result,
you are cautioned not to rely on these forward-looking statements.
These and other risks concerning Akcea's programs are
described in additional detail in Akcea's quarterly
reports on Form 10-Q and annual reports on Form 10-K, which are on
file with the SEC. Copies of these and other documents are
available from the company.
In this press release, unless the context requires otherwise,
"Ionis," "Akcea," "Company," "Companies," "we," "our," and "us"
refers to Ionis Pharmaceuticals and/or Akcea
Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis
Pharmaceuticals, Inc., Akcea Therapeutics®,
TEGSEDI® and WAYLIVRA® are trademarks
of Akcea Therapeutics, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/akcea-therapeutics-to-hold-second-quarter-2020-financial-results-webcast-301095839.html
SOURCE Akcea Therapeutics, Inc.